Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rx Africa Ethiopia, a wholly owned operating subsidiary of Rx for Africa, Inc has announced that its newly completed R&D center has formulated nine generic pharmaceuticals, and is on track to launch a minimum of 36 new products in 2009.
Subscribe to our email newsletter
According to the company, the malaria drug Artemisinin is scheduled for a third-quarter launch in 2009, and HIV/AIDS pharmaceuticals are in process.
Mulugetta Bezzabeh, CEO of Rx for Africa, Inc said: “Our launch list of generic pharmaceuticals includes many standard antibiotics, anti-fungals, anti-inflammatory and analgesic drugs that are taken for granted in the US and developed world, but of which there are still extreme shortages in Ethiopia, and throughout Sub-Saharan Africa.
“Our staff in Ethiopia, including scientists from India and Germany, is now accomplishing this important work and meeting or exceeding scheduling milestones.”